pidemiological studies have shown that HDL cholesterol levels are inversely correlated with the risk of developing coronary heart disease. [1] [2] [3] This inverse association is present in both men and women and is due to the important role played by HDL in the reverse cholesterol transfer pathway, in which HDL functions as an acceptor of excess cholesterol from peripheral cells and transports it back to the liver for removal. Apolipoprotein A-I (apo A-I) is the major protein constituent of HDL and is required for HDL formation, as indicated by the presence of very low levels of HDL cholesterol in subjects with apo A-I gene deletions or rearrangements. 4 -6 Also, apo A-I is sufficient for HDL formation, as shown in fibroblasts transfected with an expression vector containing the apo A-I gene. 7 Epidemiological studies have shown that postmenopausal women on estrogen replacement therapy have a lower risk of heart disease than women who do not take estrogen. 8 Estrogen has been shown to significantly affect plasma lipid levels by lowering LDL cholesterol and apo B levels and by increasing HDL cholesterol and apo A-I levels in both premenopausal and postmenopausal women. 9 -11 The estrogen-mediated increase in plasma HDL cholesterol and apo A-I levels is one of several mechanisms responsible for the protection exerted by estrogen against cardiovascular disease in women. Metabolic studies have demonstrated that the increase in apo A-I levels by estrogen is due to an increase in apo A-I production rate, with nonsignificant effects on apo A-I catabolism. 9, 12, 13 In humans, the apo A-I gene is expressed in both liver and intestine, and studies in Hep G2 cells, a human hepatoma cell line, have demonstrated that estrogen can increase apo A-I concentration in the medium of these cells in a dose-dependent manner. 14, 15 This effect is paralleled by an increase in apo A-I mRNA steady-state levels. 14, 15 In most genes, the mRNA levels are modulated by estrogen by 2 major mechanisms. The most common mechanism is the direct regulation of the transcription activity of the gene by interaction of the estrogen/estrogen-receptor complex with a specific DNA sequence called the estrogen response element (ERE). 16 In some genes, estrogen has been shown to promote transcription through the AP-1 site, a binding site for Fos and Jun, possibly by an estrogen receptor (ER)-independent mechanism. 17 Alternatively, estrogen can modulate levels of a specific mRNA by affecting its degradation. 18, 19 The 5Ј region of the apo A-I gene between nucleotides Ϫ222 and Ϫ110 contains regulatory elements that are necessary for transcription of this gene in hepatic cells. 20, 21 This region, known as the apo A-I hepatic enhancer, contains 3 different DNA binding elements, A (Ϫ214 to Ϫ192), B (Ϫ169 to Ϫ146), and C (Ϫ134 to Ϫ119), which have been shown to bind several nuclear transcription factors. [22] [23] [24] In addition, the intergenic region between the apo C-III and apo A-IV genes (located in a cluster with the apo A-I gene on the same chromosome within a 15-kb DNA fragment) contains additional DNA elements that enhance and regulate the expression of the apo A-I gene governed by the apo A-I hepatic enhancer. 25 In this study, we examined the 5Ј and 3Ј DNA regions of the apo A-I gene to understand the mechanism responsible for the estrogen responsiveness of apo A-I gene expression.
Methods

Cell Culture
Hep G2 cells were grown in high-glucose DMEM (BioWhittaker) supplemented with 10% FBS (Hyclone) and 100 U/mL penicillin, 100 g/mL streptomycin, 1% Glutamax, and 1% MEM amino acids (Life Technologies) in 5% CO 2 atmosphere at 37°C. In experiments in which estrogen (17␤-estradiol [E 2 ], Sigma) was added to the cell medium, cells were plated on 60-mm dishes at a density of 1.2ϫ10 6 cells/dish with phenol red-free DMEM containing 10% charcoal/ dextran-treated FBS (Hyclone); after 24 hours, cells were washed and incubated in serum-free medium; on day 3, fresh serum-free media were added to cells, together with E 2 dissolved in 95% ethanol (control cells received ethanol only). On day 4, cells were collected for the isolation of RNA, and cell culture media were collected for the measurement of total protein and apo A-I concentrations. Unless otherwise stated, a concentration of 10 mol/L E 2 was used in all experiments. A water-soluble form of E 2 (Sigma) was used in some experiments, after we documented that Hep G2 cells responded to the ethanol-soluble and the water-soluble forms of E 2 in an identical manner.
Total RNA was isolated according to the guanidinium thiocyanate method followed by ultracentrifugation over a cesium chloride cushion, as previously described. 26 Analysis of mRNA was performed by Northern blot analysis followed by hybridization with specific biotinylated probes (Life Technologies) for apo A-I and ␤-actin. Quantification of mRNA signals was performed by densitometric scanning of autoradiographic bands of apo A-I and ␤-actin messages by use of an LKB laser densitometer (Pharmacia). The apo A-I mRNA levels were expressed as the ratio of apo A-I to ␤-actin.
Apo A-I concentration in conditioned media was measured with an ELISA developed in our laboratory, 27 in which cell-conditioned media were tested at a 1:100 dilution instead of the 1:60 000 dilution used for measurement of apo A-I concentrations in plasma samples. The concentration of apo A-I was expressed as g apo A-I/g total proteinϫ10 Ϫ3 .
Plasmid Construction
Plasmid Ϫ2500A-I(C-III/A-IV).Luc (a gift from Dr S. Karathanasis, Wyeth-Ayerst Laboratories, St. Davids, PA) contains the Ϫ2500 to ϩ397 region of the human apo A-I gene cloned in the HindIII site in front of the luciferase gene and 7 kb of the apo C-III/apo A-IV intergenic region in the BamHI site in the pGL2 basic vector (Promega). 28 Plasmid Ϫ2500A-I.Luc was constructed by cutting plasmid Ϫ2500A-I(C-III/A-IV). Luc. Correct orientation of cloning during plasmid construction was always determined by diagnostic cuts with several restriction enzymes. Also, the 5Ј region of the apo A-I gene in the Ϫ256A-I.Luc plasmid was sequenced, and its nucleotide sequence was identical to that previously published. 20 The ER-␣ expression vector has been previously described 28 and was obtained by cloning the EcoRI fragment containing the cDNA region of the ER-␣ from the HEO plasmid 29 into the pMT2 expression vector. 30 
Cell Transfection
Transfection of Hep G2 cells was carried out with the Lipofectamine reagent (Life Technologies). Briefly, cells were plated on 60-mm dishes, as described above, and on day 2 were transfected with 2 g of RSV-␤-galactosidase plasmid and 3 g (or the molar equivalent) of apo A-I promoter/luciferase constructs in the presence of 20 L of Lipofectamine for 14 hours in serum-free and antibiotic-free conditions; on day 3, cells were washed and incubated in fresh serum-free medium, and estrogen was added at a final concentration of 10 mol/L; on day 4, cells were collected by scraping the bottom of culture dishes. Cell extracts were stored at Ϫ70°C until ␤-galactosidase and luciferase activities were assayed. The activities of these enzymes were measured with commercially available kits from Promega. Media were also collected for the measurement of apo A-I concentrations.
Cells were also transfected by the calcium phosphate precipitation method as previously described. 31 
Statistical Analysis
Experiments were conducted in duplicate. Data presented are the meanϮSD of Ն2 separate experiments. Statistical significance was determined with Student's t test. Differences were considered significant at a value of PϽ0.05.
Results
Incubation of Hep G2 cells with different concentrations of E 2 for 24 hours resulted in a dose-dependent increase in apo A-I concentration in the media (Figure 1 ). The apo A-I concentration, relative to total protein concentration, in cells exposed to 10 mol/L E 2 was 4.3Ϯ1.0-fold greater than in control cells (nϭ6, PϽ0.001), and in cells exposed to 1 mol/L E 2 , it was 1.8Ϯ0.4-fold greater than in control cells (nϭ4, Pϭ0.09). E 2 at 10 nmol/L and 100 nmol/L concentration did not significantly affect apo A-I secretion by Hep G2. A time-course experiment indicated that when cells were incubated for 0, 1, 2, 6, and 24 hours in 10 mol/L E 2 , apo A-I increased in cells treated with estrogen compared with control cells at Ϸ6 hours, when a 65% increase in apo A-I was observed, and the increase in apo A-I reached 4.4-fold at 24 hours ( Figure 2) .
As shown in the Table, the estrogen-related increase in apo A-I concentration in the medium was associated with an increase in specific apo A-I mRNA steady-state levels, relative to ␤-actin mRNA levels, in the cells. ␤-Actin was chosen as a reference gene because it is a housekeeping gene and its expression is not regulated by estrogen.
The increase in apo A-I mRNA steady-state levels suggested either an increase in transcriptional activation of the apo A-I gene or a decrease in mRNA degradation. The transcriptional activity of the apo A-I gene in the presence of estrogen was tested in a series of transfection experiments. Because it has been shown that the apo C-III/apo A-IV intergenic region contains elements that are important in the activation of transcription of the apo A-I gene, 2 series of constructs were used: constructs containing serial deletions of the 5Ј region of the apo A-I gene, with or without the apo C-III/apo A-IV intergenic region. As shown in Figure 3 , the plasmid constructs containing only 41 bp of the 5Ј region of the apo A-I gene did not respond to estrogen administration. The plasmids containing 256 bp of the 5Ј region of the apo A-I gene were the shortest constructs to maintain estrogen responsiveness. The presence of the apo C-III/A-IV intergenic region did not affect estrogen responsiveness. In these transfection experiments, where a reagent consisting of cationic liposomes was used, cells treated with estrogen also showed the characteristic 4-fold increase in apo A-I concentration in the medium. However, when the same transfection experiments were performed by the calcium phosphate precipitation method, the estrogen responsiveness was nearly abolished both at the level of the transcriptional activity of the apo A-I gene and of the apo A-I concentration in the medium (data not shown): only a 10% increase (PϭNS) in apo A-I in the medium was observed under these conditions, with no change in the transcriptional activity. Hep G2 cells were grown as described in the Methods section. After exposure for 24 hours to the indicated E 2 concentrations, media were collected and apo A-I was measured. The apo A-I concentration is calculated as the ratio between apo A-I (g/mL) and total protein (g/mL) in the medium and is expressed as percentage of control cells. indicating a role of calcium in the modulation of apo A-I transcription by estrogen. We investigated whether ER plays a role in the increased production of apo A-I in Hep G2 cells by estrogen. Plasmid Ϫ41A-I.Luc and Ϫ256A-I.Luc were cotransfected with increasing amounts of an ER-␣ expression vector. As indicated in Figure 5 , increasing amounts of ER-␣ were associated with decreasing activity of the apo A-I gene promoter in the presence of estrogen, so that at 0.5 g of ER-␣ plasmid, the transcriptional activity of the apo A-I promoter was approximately half that of control. A plasmid construct containing the luciferase gene under the control of the tk promoter and 2 ERE (5Ј-GGTCANNNTGACC-3Ј) was also used in transfection experiments in the presence or absence of E 2 . As shown in Figure 6 , the transcription of this construct failed to be activated by E 2 alone but was activated severalfold in the presence of both E 2 and ER-␣.
Effect of E 2 on Steady-State Levels of Apo A-I mRNA in Hep G2 Cells
Discussion
Because of the inverse relationship between HDL and apo A-I levels and the risk of coronary heart disease in the general population, factors that regulate and, in particular, increase plasma levels of these parameters are of great interest for their potential health benefits. It has been projected that for each 0.026-mmol/L increase in HDL cholesterol levels, the risk of coronary heart disease decreases by 2% to 3%. 32 Estrogen has clearly been shown to fall in the category of HDL cholesterol-raising drugs. However, clinical studies have shown that the route of administration of estrogen influences its effects on HDL cholesterol levels. It has been shown that transdermal administration of estrogen does not significantly increase HDL cholesterol levels in postmenopausal women, even though serum estradiol levels in these women are raised to premenopausal levels. 13 Oral administration of estrogen results in a 15% to 36% increase in HDL cholesterol levels. 12, 13 This suggests that exposure of hepatic cells to higher levels of estrogen, as obtained in the oral administration, may be necessary for estrogen to exert its effects on plasma lipids. The present study indicates that E 2 , at the superphysiological concentrations of 1 and 10 mol/L, increases the synthesis of apo A-I by hepatic cells. These results are in agreement with those of 2 previous studies in Hep G2 cells using E 2 concentrations of 10 nmol/L 14 and 10 mol/L. 15 We found that the increase in apo A-I synthesis by hepatic cells is accompanied by an increase in apo A-I mRNA levels, as also shown in previous studies. 14,15 However, Harnish et al 28 recently found that apo A-I mRNA levels were not affected by treatment with 1 mol/L E 2 in Hep G2 cells. The reason for this discrepancy in results is not clear.
As indicated by the time-course experiment, the rate at which apo A-I levels increase in the medium of Hep G2 cells treated with E 2 is slow, starting at Ϸ6 hours after the addition of estrogen in the medium. This was also observed by Archer et al 14 and suggests that the mechanism responsible for the increase in apo A-I production by hepatic cells does not involve an immediate response but rather requires induction.
Apo A-I mRNA levels may be regulated either at the transcriptional level or by posttranscriptional mechanisms. It has been shown that estrogen does not affect the degradation of apo A-I mRNA. 15 We have tested the hypothesis that the E 2 -related increase in apo A-I mRNA is due to increased transcriptional activity of the gene. Transfection experiments with plasmids containing serial deletions of the 5Ј region of the apo A-I gene, with or without the apo C-III/A-IV intergenic region, indicated that the estrogen responsiveness Figure 4 . Effect of calcium on the estrogen-mediated increase in apo A-I concentrations in Hep G2 cell media. Different concentrations of CaCl 2 were added to the media of Hep G2 cells in the presence or absence of 10 mol/L E 2 for 24 hours. The apo A-I concentration is calculated as the ratio between apo A-I (g/mL) and total protein (g/mL) and is expressed as percentage of control cells (no estrogen added). is maintained in the plasmid constructs containing 256 bp of the 5Ј region of the apo A-I gene and is not affected by the apo C-III/A-IV intergenic region. The DNA region that extends to 256 bp upstream of the start site of the apo A-I gene contains the apo A-I hepatic enhancer, which has been shown to be necessary and sufficient for expression of this gene in liver cells. 21 The hepatic enhancer is composed of 3 different regions, A, B, and C, which bind to different nuclear transcription factors. [22] [23] [24] This region does not contain a canonical ERE binding site, but site A contains half of the canonical ERE sequence (TGACC) separated by 3 nucleotides by a tandem imperfect repetition (TGAAC). There are numerous examples in the literature of estrogen-responsive genes containing noncanonical ERE in their 5Ј flanking region: it has been shown that the rabbit uteroglobulin gene, 33 the mouse lactoferrin gene, 34 and the human pS2 gene 35 contain an imperfect ERE. Also, it has been shown that the chicken ovalbumin gene contains several half-palindromic motifs that confer estrogen inducibility to the gene by acting synergistically. 36 The lower affinity for the ER of these DNA sequences may be responsible for the lower induction of transcription of these genes by estrogen compared with the classic ERE-containing genes. 34, 35 However, we have conducted preliminary experiments with plasmid constructs containing mutations of site A of the human apo A-I gene, and our results indicate that mutations in either of the putative ERE half-sites do not affect estrogen responsiveness (data not shown).
Two isoforms of ER, ER-␣ and ER-␤, have been described. Until recently, only ER-␣ was known, but in 1996 ER-␤ was isolated by Kuiper et al. 37 Hep G2 cells have been shown to contain ER-␤, specifically isoform 5, in low amounts. 38 Even though it has been shown that ER-␤ can bind to the same DNA sequence as ER-␣, it has been speculated that ER-␤ may also bind to different and as yet uncharacterized sequences. 39 The observation that cotransfection of the estrogen-responsive apo A-I plasmid with increasing amounts of an expression vector for ER-␣ progressively decreases the estrogen-related expression of apo A-I and that at the higher dose ER-␣ actually inhibits the transcription of the apo A-I gene seems to indicate that ER-␣, when present in high concentration in the cell nucleus, competes with other transcription factors for binding to the enhancer region or, as suggested previously, 28 competes for binding to a coactivator common to the factors binding to the enhancer. In both cases, partitioning of the relevant regulatory protein to the ER may lead to decreased activation of the enhancer. Our transfection experiments with the Ϫ256A-I.Luc construct and with an ERE construct with or without ER-␣ suggest that the mechanism of transcription activation of the apo A-I gene by estrogen is different from the classic ER-␣-mediated regulation of transcription. It is not known whether apo A-I gene transcription is regulated by the ER-␤ differently than by ER-␣.
We have observed that Hep G2 cells, when transfected with the cationic lipid methods, maintained their estrogen responsiveness by increasing the amount of apo A-I secreted in the medium after exposure to E 2 . However, it was interesting to observe that in similar transfection experiments using the classic calcium phosphate precipitation method, cells ceased to respond to estrogen by showing a lack of increase in apo A-I in the medium after exposure to estrogen. This effect was paralleled by a lack of transcription activation of the apo A-I gene by estrogen. Harnish et al 28 recently published data indicating that the apo A-I promoter does not respond to estrogen. In their study, transfection experiments were carried out with the classic calcium phosphate method, and therefore, the discrepancy in results between our study and the study by Harnish et al may be explained by the methodology used. In an attempt to define the problem related to the calcium phosphate technique, we have exposed Hep G2 cells grown in the presence of E 2 to different calcium concentrations. The estrogen-related increase in apo A-I in the medium was nearly abolished when cells were exposed to calcium concentrations similar to those used in the precipitation method. The mechanism responsible for this effect of calcium is unclear, but it has been shown that calcium can modulate the interaction of the ER with its ligand. 40, 41 Our results indicate that the apo A-I gene is regulated by estrogen at the transcriptional level. The estrogen-related activation in transcription leads to increased levels of mRNA for apo A-I and increased synthesis of apo A-I by hepatic cells. The DNA region of the apo A-I gene involved in the activation of transcription is located in the first 256 bp 5Ј of the gene. Because this region does not contain a classic ERE, it is possible that estrogen can activate transcription indirectly through induction of other transcription factors.
